Pharmamarketeer

Astellas begins phase 3 trials of fezolinetant in postmenopausal women with vasomotor symptoms

Astellas Pharma Inc announced dosing of the first patient in the SKYLIGHT 1 phase 3 pivotal trial for fezolinetant, an investigational oral, non─hormonal compound being studied for the treatment of moderate─to─severe vasomotor symptoms

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl